Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus

These guidelines are developed under the auspices of the American College of Gastroenterology (ACG) and its Practice Parameters Committee and approved by the Board of Trustees. They have been intensely reviewed and revised by the Committee, other experts in the field, physicians who will use them, and specialists in the science of decision analysis. When approved by the ACG, they are submitted to the other major gastrointestinal societies (American Gastroenterolgical Association and the American Society for Gastrointestinal Endoscopy) for their review and approval. To develop the guidelines, the world literature is searched, then all appropriate studies are reviewed and evaluated by the authors. In the literature review, evidence is evaluated along a hierarchy with randomized, controlled trials given the greatest weight. No randomized controlled trials are available to address the issues in this guideline. Recommendations are based on large observational series and expert opinion. Abstracts presented at national and international meetings are used only in special circumstances in which unique data from ongoing trials were presented. These guidelines are intended to be applicable to all physicians who address the subject without regard to specialty training or interests and are intended to indicate the preferable, but not the only acceptable, approach to this problem. Given the wide range of specifics in any health care problem, the physician must always choose the course best suited to the individual patient and the variables in existence at the moment of decision.

[1]  Patricia L. Blount,et al.  An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. , 1993, Gastroenterology.

[2]  J. Peters,et al.  Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. , 1994, The Journal of thoracic and cardiovascular surgery.

[3]  M. Johnston,et al.  The prevalence and clinical characteristics of short segments of specialized intestinal metaplasia in the distal esophagus on routine endoscopy. , 1996, The American journal of gastroenterology.

[4]  Treatment of Barrett's metaplasia by antireflux surgery and endoscopic laser ablation: Clinical experience in ten patients , 1995 .

[5]  R. Sampliner,et al.  Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: preliminary results. , 1996, Gastrointestinal endoscopy.

[6]  D. Castell,et al.  Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. , 1995, Archives of internal medicine.

[7]  T. Hennessy,et al.  Proliferating cell nuclear antigen in the assessment of Barrett's mucosa , 1994, The British journal of surgery.

[8]  F. Ellis,et al.  Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. , 1978, American journal of clinical pathology.

[9]  G. Lapertosa,et al.  Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. , 1996, Gastrointestinal endoscopy.

[10]  P. Stevens,et al.  Hypertensive emergency and ventricular tachycardia after endoscopic epinephrine injection of a Mallory-Weiss tear. , 1994, Gastrointestinal endoscopy.

[11]  R. Sampliner,et al.  Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. , 1997, The American journal of gastroenterology.

[12]  A. Cameron,et al.  Adenocarcinoma of the esophagogastric junction and Barrett's esophagus. , 1995, Gastroenterology.

[13]  D. Katzka,et al.  Successful elimination of reflux symptoms does not insure adequate control of acid reflux in patients with Barrett's esophagus. , 1994, The American journal of gastroenterology.

[14]  A R Zinsmeister,et al.  Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. , 1993, Gastroenterology.

[15]  Carissa A. Sanchez,et al.  p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. , 1994, Gastroenterology.

[16]  N. Walker,et al.  Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. , 1991, Gut.

[17]  J. Jankowski,et al.  Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: Biological and clinical variables , 1995, International journal of cancer.

[18]  S. Spechler,et al.  Scanning electron microscopy of Barrett's epithelium and its correlation with light microscopy and mucin stains. , 1986, Gastroenterology.

[19]  R. Heitmiller,et al.  Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. , 1996, Annals of surgery.

[20]  J. Mayberry,et al.  Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus , 1988, The British journal of surgery.

[21]  R. Sampliner,et al.  Ornithine decarboxylase activity in Barrett's esophagus: a potential marker for dysplasia. , 1988, Gastroenterology.

[22]  D J Ballard,et al.  Prevalence of columnar-lined (Barrett's) esophagus. Comparison of population-based clinical and autopsy findings. , 1990, Gastroenterology.

[23]  P. Dítě,et al.  [Barrett's esophagus]. , 2000, Bratislavske lekarske listy.

[24]  J. Richter,et al.  Role of acid and duodenogastroesophageal reflux in gastroesophageal reflux disease. , 1996, Gastroenterology.

[25]  D. Hopwood,et al.  Flow-cytometric analysis of growth-regulatory peptides and their receptors in Barrett's oesophagus and oesophageal adenocarcinoma. , 1992, Scandinavian journal of gastroenterology.

[26]  J. Pignon,et al.  Surgical pathology of adenocarcinoma arising in Barrett's esophagus. Analysis of 67 cases. , 1995, The American journal of surgical pathology.

[27]  D. Skinner,et al.  Barrett's esophagus. Functional assessment, proposed pathogenesis, and surgical therapy. , 1983, Archives of surgery.

[28]  W. Hop,et al.  Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. , 1995, Gut.

[29]  G Whelan,et al.  Prevalence of columnar-lined (Barrett's) esophagus. , 1991, Gastroenterology.

[30]  C. Winters,et al.  Esophageal acid sensitivity in Barrett's esophagus. , 1987, Journal of clinical gastroenterology.

[31]  M. Helfand,et al.  Risk factors for Barrett's esophagus in community-based practice. GORGE consortium. Gastroenterology Outcomes Research Group in Endoscopy. , 1997, The American journal of gastroenterology.

[32]  R. Goyal,et al.  Prevalence of metaplasia at the gastro-oesophageal junction , 1994, The Lancet.

[33]  J. Fraumeni,et al.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.

[34]  A. Bhattacharyya,et al.  Intestinal metaplasia of the gastric cardia. , 1997, The American journal of gastroenterology.

[35]  T. Demeester,et al.  Functional foregut abnormalities in Barrett's esophagus. , 1993, The Journal of thoracic and cardiovascular surgery.

[36]  J. Rosenberg,et al.  Analysis of adenocarcinoma in barrett's esophagus utilizing a staging system , 1985, Cancer.

[37]  J. Richardson,et al.  The rationale for esophagectomy as the optimal therapy for Barrett's esophagus with high-grade dysplasia. , 1996, Annals of surgery.

[38]  G Van Belle,et al.  Observer variation in the diagnosis of dysplasia in Barrett's esophagus. , 1988, Human pathology.

[39]  B. Reid,et al.  Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. , 1987, Gastroenterology.

[40]  R. Hunt,et al.  A study to examine agreement between endoscopy and histology for the diagnosis of columnar lined (Barrett's) esophagus. , 1989, Gastrointestinal endoscopy.

[41]  J. Freston,et al.  Critical issues in the management of gastroesophageal reflux disease. , 1995, European journal of gastroenterology & hepatology.

[42]  D. Lane,et al.  Epithelial proliferation in Barrett's esophagus by proliferating cell nuclear antigen immunolocalization. , 1992, Gastroenterology.

[43]  G. Meyer,et al.  Guidelines for the Diagnosis and Treatment of Gastroesophageal Reflux Disease , 1995 .

[44]  J. Peters,et al.  Is Barrett's metaplasia the source of adenocarcinomas of the cardia? , 1994, Archives of surgery.

[45]  R. Sampliner,et al.  Discordance between flow cytometric abnormalities and dysplasia in Barrett's esophagus. , 1989, Gastroenterology.

[46]  J. Boitnott,et al.  The spectrum of carcinoma arising in Barrett's esophagus: A clinicopathologic study of 26 patients , 1984, The American journal of surgical pathology.

[47]  D. Grueneberg,et al.  DNA content in Barrett's esophagus and esophageal malignancy. , 1987, The American journal of gastroenterology.

[48]  C. Lightdale,et al.  Combined magnification endoscopy with chromoendoscopy for the evaluation of Barrett's esophagus. , 1994, Gastrointestinal endoscopy.

[49]  R. Lebovitz,et al.  p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study. , 1993, Gastroenterology.

[50]  B. Overholt,et al.  Photodynamic therapy for Barrett's esophagus: clinical update. , 1996, The American journal of gastroenterology.

[51]  R. R. Smith,et al.  Prevalence and characteristics of Barrett esophagus in patients with adenocarcinoma of the esophagus or esophagogastric junction. , 1988, Human pathology.

[52]  C. Winters,et al.  In vivo staining with toluidine blue as an adjunct to the endoscopic detection of Barrett's esophagus. , 1987, Gastrointestinal endoscopy.

[53]  D. Ransohoff,et al.  Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. , 1983, Human pathology.

[54]  R. Sampliner,et al.  The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. , 1997, The American journal of gastroenterology.

[55]  A. Bhattacharyya,et al.  Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up. , 1997, The American journal of gastroenterology.

[56]  D. Skinner,et al.  Barrett's Esophagus: Comparison of Benign and Malignant Cases , 1983, Annals of surgery.

[57]  P. Blount,et al.  Evaluation of p53 protein expression in Barrett's esophagus by two-parameter flow cytometry. , 1992, Gastroenterology.

[58]  R. Sandler,et al.  The relationship between gastroesophageal reflux disease and its complications with Barrett's esophagus. , 1997, The American journal of gastroenterology.

[59]  J. G. van den Tweel,et al.  Barrett's esophagus: development of dysplasia and adenocarcinoma. , 1989, Gastroenterology.

[60]  P. Blount,et al.  Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. , 1992, Gastroenterology.

[61]  W. Macdonald,et al.  Adenocarcinoma of the Esophagus and/or Gastric Cardia , 1987, Cancer.

[62]  R. Cherian,et al.  Short segment Barrett's esophagus: clinical and histological features, associated endoscopic findings, and association with gastric intestinal metaplasia. , 1996, The American journal of gastroenterology.

[63]  S. Spechler Comparison of medical and surgical therapy for complicated gastroesophageal reflux disease in veterans. The Department of Veterans Affairs Gastroesophageal Reflux Disease Study Group. , 1992, The New England journal of medicine.